PMID- 18208585
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20100610
LR  - 20211020
IS  - 1750-9378 (Electronic)
IS  - 1750-9378 (Linking)
VI  - 3
DP  - 2008 Jan 21
TI  - Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune 
      reconstitution syndrome related Kaposi sarcoma.
PG  - 1
LID - 10.1186/1750-9378-3-1 [doi]
AB  - A decrease in the incidence of human immune deficiency virus-associated Kaposi 
      sarcoma (HIV-KS) and regression of some established HIV-KS lesions is evident 
      after the introduction of highly active anti-retroviral treatment (HAART), and is 
      attributed to generalized immune restoration, to the reconstitution of human 
      herpesvirus (HHV)-8 specific cellular immune responses, and to the decrease in 
      HIV Tat protein and HHV-8 loads following HAART. However, a small subset of 
      HIV-seropositive subjects with a low CD4+ T cell count at the time of 
      introduction of HAART, may develop HIV-KS as immune reconstitution inflammatory 
      syndrome (IRIS) within 8 weeks thereafter.
FAU - Feller, Liviu
AU  - Feller L
AD  - Department of Periodontology and Oral Medicine, Box D26 School of Dentistry, 
      University of Limpopo Medunsa Campus, Pretoria, South Africa. 
      lfeller@medunsa.ac.za
FAU - Lemmer, Johan
AU  - Lemmer J
LA  - eng
PT  - Journal Article
DEP - 20080121
PL  - England
TA  - Infect Agent Cancer
JT  - Infectious agents and cancer
JID - 101276559
PMC - PMC2265259
EDAT- 2008/01/23 09:00
MHDA- 2008/01/23 09:01
PMCR- 2008/01/21
CRDT- 2008/01/23 09:00
PHST- 2007/11/07 00:00 [received]
PHST- 2008/01/21 00:00 [accepted]
PHST- 2008/01/23 09:00 [pubmed]
PHST- 2008/01/23 09:01 [medline]
PHST- 2008/01/23 09:00 [entrez]
PHST- 2008/01/21 00:00 [pmc-release]
AID - 1750-9378-3-1 [pii]
AID - 10.1186/1750-9378-3-1 [doi]
PST - epublish
SO  - Infect Agent Cancer. 2008 Jan 21;3:1. doi: 10.1186/1750-9378-3-1.